TGTX: TG Therapeutics Inc Company Profile & Statistics

About

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Info & Links

CEO

Michael S. Weiss

Headquarters

3020 CARRINGTON MILL BLVD, SUITE 475
MORRISVILLE, NY 27560, UNITED STATES

Auditor

KPMG LLP

Share holders

214

Employees

264

TG Therapeutics Inc Statistics

Valuation Measures

Market Capitalization²

5.10B

Enterprise Value

5.15B

Enterprise Value/EBITDA(ttm)

-1.10K

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

18.82

Price to Book(mrq)

25.80

Price to Cash(ytd)

366.26

Profitability

Gross Margin(ttm)

87.78%

Operating Margin(ttm)

-5.42%

Profit Margin(ttm)

-8.92%

Return on Equity(ttm)

-8.32%

Return on Invested Capital(ttm)

-6.28%

Return on Assets(ttm)

-3.40%

Income Statement

Revenue(ttm)

264.79M

Revenue Per Share(ttm)

1.70

Gross Profit(ttm)

233.85M

EBITDA(ttm)³

-4.68M

Net Income Available to Common(ttm)

-14.36M

Diluted EPS(ttm)

-0.10

Share Statistics

Beta (5Y Monthly)

2.25

52-Week Change

127.39%

S&P 500 52-Week Change

27.92%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

155.67M

Dividend Yield

0.00%

Float⁴

139.32M

% Held by Insiders

10.50%

% Held by Institutions

58.58%

Balance Sheet

Total Cash(mrq)

341.04M

Total Cash Per Share(mrq)

2.19

Total Debt(mrq)

244.16M

Total Debt/Equity(mrq)

127.06%

Current Ratio(mrq)

4.59%

Quick Ratio(mrq)

3.91%

Book Value Per Share(mrq)

1.23

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.09

Free Cash Flow(ytd)

-14.90M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

TGTX

TG Therapeutics Inc

TG Therapeutics Inc Profile